1813908

Source:http://linkedlifedata.com/resource/pubmed/id/1813908

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0085208, umls-concept:C0178602, umls-concept:C0456081, umls-concept:C1527178, umls-concept:C1705938, umls-concept:C1720825
pubmed:issue	4
pubmed:dateCreated	1992-6-12
pubmed:abstractText	Bupropion is the next antidepressant which should be studied aggressively to test the value of therapeutic drug monitoring (TDM). This paper will present the basis for this conclusion.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0101123
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Bupropion
pubmed:status	MEDLINE
pubmed:issn	0048-5764
pubmed:author	pubmed-author:PreskornS HSH
pubmed:issnType	Print
pubmed:volume	27
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	637-43
pubmed:dateRevised	2009-11-11
pubmed:meshHeading	pubmed-meshheading:1813908-Bupropion, pubmed-meshheading:1813908-Depressive Disorder, pubmed-meshheading:1813908-Drug Monitoring, pubmed-meshheading:1813908-Humans
pubmed:year	1991
pubmed:articleTitle	Should bupropion dosage be adjusted based upon therapeutic drug monitoring?
pubmed:affiliation	Psychiatric Research Institute, St. Francis Regional Medical Center, Wichita, KS 67214.
pubmed:publicationType	Journal Article, Review